Paper Details

  1. Home
  2. Paper Details

Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.

Author: CaiHong-Qing, CaiYan, ChengZhi-Jian, DuGuan-Hua, FanZhi-Lu, HaoJia-Jie, LiuZou, WangDi, WangJin-Hua, WangMing-Rong, XuXin, YangLi-Yan, ZhangNa, ZhangYu

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Afatinib, an EGFR inhibitor, showed significant anti-tumor effects in esophageal squamous cell carcinoma (ESCC) cells with high p-EGFR expression. For patients with lower p-EGFR expression, a combination of paclitaxel and afatinib may be a promising therapeutic strategy.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIM: Chemotherapy drugs do not work well in esophageal squamous cell carcinoma (ESCC), and none of the targeted drugs have been applied in clinic. This study aims to identify effective targeted drugs and related biomarkers for the treatment of ESCC. METHODS: The effect of 40 Food and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jgh.15490

データ提供：米国国立医学図書館（NLM）

Afatinib: A Promising Targeted Therapy for Esophageal Squamous Cell Carcinoma

This research delves into the intricate landscape of esophageal squamous cell carcinoma (ESCC), a challenging cancer that affects the esophagus. The study investigates the potential of afatinib, a targeted therapy, as a treatment option for ESCC. The researchers conducted a series of in vitro and in vivo experiments, exploring the efficacy of afatinib alone and in combination with paclitaxel, another chemotherapy drug. Their findings suggest that afatinib, like a skilled desert navigator, holds promise as a targeted therapy for ESCC, with the potential to improve outcomes for patients battling this disease.

A Targeted Approach to Cancer Treatment

This research highlights the potential of afatinib as a targeted therapy for ESCC. The study's findings suggest that afatinib, alone or in combination with paclitaxel, can effectively inhibit the growth of ESCC cells. The results demonstrate the potential of targeted therapies to provide more effective and less toxic treatment options for cancer patients.

Hope for Patients with ESCC

This research offers hope for patients battling ESCC. The study's findings suggest that afatinib, a targeted therapy, may provide a new avenue for treatment, offering the potential to improve outcomes for patients with this challenging disease. It's a reminder of the power of research and the ongoing search for innovative treatments for cancer.

Dr.Camel's Conclusion

This research explores the potential of afatinib as a promising targeted therapy for ESCC. The study's findings suggest that afatinib, alone or in combination with paclitaxel, can effectively inhibit the growth of ESCC cells. The results provide hope for patients battling this challenging disease, highlighting the potential of targeted therapies to improve outcomes and reduce the toxicity associated with conventional treatments.
Date :
  1. Date Completed 2022-03-17
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

33721913

DOI: Digital Object Identifier

10.1111/jgh.15490

Related Literature

Article Analysis
・Effects of afatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.